Murray State University, None, 1968, Chemistry
University of Kentucky, B.S., 1971, Pharmacy
University of Kentucky, Doctorate, 1979, Pharmacy

Employment

Chief, Research Support Branch, NIDA, Addiction Research Center, Baltimore, Md., 1984-91
Consultant Medical Reviewer, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Md., 1989-90
Assistant Professor of Behavioral Biology, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Md., 1991-92
Associate Professor of Behavioral Biology, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Md., 1992-Present
Clinical Assistant Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Md. at Baltimore, Baltimore, Md., 1992-95
Clinical Associate Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Md. at Baltimore, Baltimore, Md., 1995-Present.

Awards and Honors

Public Health Service (PHS) Commissioned Corps: Isolated Hardship Medal, 1978
Commendation Medal, 1980; Outstanding Service Medal, 1987
Exceptional Capability Promotion, 1988.

Memberships

American Pharmaceutical Association
American Society for Clinical Pharmacology and Therapeutics
Society Clinical Associates in Pharmacology
Society for Clinical Trials.

Professional licensure

Kentucky Board of Pharmacy
Maryland Board of Pharmacy

Publications

Sublingual versus Subcutaneous Buprenorphine in Opiate Abusers. Jasinski, D.R., Fudala, P.J., and Johnson, R.E. Journal of Clinical Pharmacology and Therapeutics, Vol. 45, pp. 513-519, May, 1989.

Use of Buprenorphine in the Treatment of Opiate Addiction I: Physiologic and Behavioral Effects During a Rapid Dose Induction. Johnson, R.E., Cone, E.J., Henningfield, J.E., and Fudala, P.J. Journal of Clinical Pharmacology and Therapeutics, Vol. 46, pp. 335-343, 1989.

Safety and Side-Effects of Buprenorphine in the Clinical Management of Heroin Addiction. Lange, W.R., Fudala, P.J., Dax, E.M., and Johnson, R.E. Alcohol and Drug Dependence, Vol. 26, pp. 19-28, 1990.

Use of Buprenorphine in the Treatment of Opioid Addiction II: Physiologic and Behavioral Effects of Daily and Alternate-Day Administration and Abrupt Withdrawal. Fudala, P.J., Jaffe, J.H., Dax, E.M., and Johnson, R.E. Journal of Clinical Pharmacology and Therapeutics, Vol. 47, pp. 525-534, April, 1990.

Human Pharmacology and Abuse Potential of Nalmefene. Fudala P.J., Heishman S.J., Henningfield J.E., and Johnson R.E. Journal of Clinical Pharmacology and Therapeutics, Vol. 49, No. 3, pp. 300-306, 1991.

The Partial Opioid Agonist, Buprenorphine, Protects Against the Lethal Effects of Cocaine. Witkin J.M., Johnson R.E., Jaffe J.H., Goldberg S.R., and Katz J.L. Drug and Alcohol Dependence, Vol. 27, pp. 177-184, 1991.

Use of Naloxone in the Assessment of Opiate Dependence. Fudala, P.J., Berkow, L.C., Fralich, J.L., and Johnson, R.E. Life Sciences, Vol. 49, pp. 1809-1814, 1991.

A Controlled Trial of Buprenorphine Treatment for Opioid Dependence. Johnson, R.E., Jaffe, J.H., and Fudala, P.J. The Journal of American Medical Association, Vol. 267, No. 20, pp. 2750-2755, 1992.

Weighing up the pros and cons: help-seeking by drug misusers in Baltimore, USA. Brooke, D., Fudala, P.J., and Johnson, R.E. Journal of Drug and Alcohol Dependence, Vol. 31, pp. 37-43, 1992.

Subjective and Physiologic Effects of Intravenous Buprenorphine in Humans. Pickworth, W.B., Johnson, R.E., Holicky, B.A., and Cone, E.J. Journal of Clinical Pharmacology and Therapeutics, Vol. 53, No. 5, pp. 570-576, 1993.

Single-dose Pharmacodynamics of Diazepam and Pentobarbital in Substance Abusers. Sullivan, J.T., Jasinski, D.R., and Johnson, R.E. Journal of Clinical Pharmacology and Therapeutics, Vol. 54, pp. 645-653, 1993.

A Comparative Study of Psychopathology and Cognitive Functions Between Cocaine- and Opiate-Dependent Patients. Montoya, I.D., Hess, J.M., Covi, L., Fudala, P.J., and Johnson, R.E. The American Journal On Addictions, Vol. 3, No. 1, pp. 36-42, 1994.

A Controlled Comparison of Buprenorphine and Clonidine for Acute Detoxification from Opioids. Cheskin, L.J., Fudala, P.J., and Johnson, R.E. Drug and Alcohol Dependence, Vol. 36, pp. 115-121, 1994.

Comparison of Psychological Symptoms Between Treatment-Seeking and Non-Treatment Seeking Drug Abusers. Montoya, I. D., Haertzen, C., Hess, J.M., Covi, L., Fudala, P.J., Johnson, R.E., and Gorelick, D.A. The Journal of Nervous and Mental Disease, Vol. 183, No. 1, pp. 50-53, 1995.

A Placebo Controlled Clinical Trial of Buprenorphine as a Treatment for Opioid Dependence. Johnson, R. E., Eissenberg, T., Stitzer, M.L., Strain, E.C., Liebson, I.A., and Bigelow, G. E. Drug and Alcohol Dependence, Vol. 40, pp. 17-25, 1995.

Buprenorphine Treatment of Opioid Dependence: A Clinical Trial of Daily versus Alternate-day Dosing. Johnson, R. E., Eissenberg, T., Stitzer, M.L., Strain, E.C., Liebson, I.A., and Bigelow, G. E. Drug and Alcohol Dependence, Vol. 40, pp. 27-35, 1995.

Assessment of Nalmefene Glucuronide as a Selective Gut Opioid Antagonist. Cheskin, L.J., Tawfik, N.C., and Johnson, R.E., Jaffe, J.H. Drug and Alcohol Dependence, Vol. 39, pp. 151-154, 1995.

Buprenorphine's Physical Dependence Potential: Antagonist-Precipitated Withdrawal in Humans. Eissenberg, T., Greenwald, M.K., Johnson, R.E., Liebson, I.A., Bigelow, G.E., and Stitzer, M.L. The Journal of Pharmacology and Experimental Therapeutics, Vol. 276, No. 2, pp. 449-459, 1996.

Human Pharmacokinetics of Intravenous, Sublingual and Buccal Buprenorphine. Kuhlman, J.J., Lalani, S., Magluilo, J., Levin, B., Darwin, W.D., Johnson, R.E., and Cone, E.J. Journal of Analytical Toxicology., Vol. 20, 369-378, 1996.

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Eissenberg, T., Johnson, R.E., Bigelow, G.E., Walsh, S.L., Liebson, I.A., Strain, E.C., and Stitzer, M.L. Drug and Alcohol Dependence, Vol. 45, pp. 81-91, 1997.

Dose-Related Efficacy of Levomethadyl Acetate for Treatment of Opioid Dependence: A Randomized Clinical Trial. Eissenberg, T, Bigelow, G.E., Strain, E.C. , Walsh, S.L., Brooner, R.K., Stitzer, M.L, and Johnson, R.E. The Journal of American Medical Association, Vol. 277, No. 24, pp. 1945-1951, 1997.

Relationship of Plasma Buprenorphine and Norbuprenorphine to Withdrawal Symptoms During Dose Induction, Maintenance and Withdrawal from Sublingual Buprenorphine. Kuhlman Jr., J.L., Levin, B., Johnson, R.E., Fudala, P.J., and Cone, E.J. Addiction, Vol. 93, No. 4, pp. 549-559, 1998.

Intravenous and oral l-alpha-acetylmethadol: Pharmacodynamics and pharmacokinetics in humans. Walsh, S.L., Johnson, R.E., Cone, E.J., and Bigelow, G.E. The Journal of Pharmacology and Experimental Therapeutics, Vol. 285, No. 1, pp. 71--82, 1998.

Dose response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. Houtsmuller, E.J., Walsh, S.L., Schuh, K.J., Johnson, R.E., Stitzer, M.L., and Bigelow, G.E. (The Journal of Pharmacology and Experimental Therapeutics, Vol. 285, No. 2, pp. 387-396, 1998.

Induction with Levomethadyl Acetate: Safety and Efficacy. Jones, H.E., Strain, E.C., Bigelow, G.E., Walsh, S.L., Stitzer, M.L., Eissenberg, T., and Johnson, R.E. Archives of General Psychiatry, Vol. 55, pp. 729-736, 1998

Human pharmacology and abuse potential of an enkephalin-like pentapeptide: BW942C. Johnson, R.E., Jones, H.E., and Jasinski, D.R. Analgesia, Vo. 4, pp. 19-26, 1999.

Treatment of opioid-dependent pregnant women with buprenorphine. Fischer, G., Johnson, R.E., Eder, H., Jagsch, R., Peternell, A., Weninger, M., Langer, M., Aschauer, H.N. Addiction , Vol. 95, pp 239-244, 2000.

Nalmefene: Blockade of Intravenous Morphine Challenge Effects in Opiate Abusing Humans. Jones, H.E., Johnson, R.E., Fudala, P.J., Henningfield, J.E. and Heischman, S.J. (In Press: Drug and Alcohol Dependence)

E-mail contact: rejohnso@jhmi.edu